The objective of this study was to successfully synthesize epidermal growth factor receptor monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles (EGFRmAb-SPIONs) and explore their biocompatibility and potential applications as a targeted magnetic resonance imaging (MRI) contrast agent for the EGFR-specific detection of brain glioma in vivo. After conjugation of EGFRmAb with SPIONs, the magnetic characteristics of EGFRmAb-SPIONs were investigated. Thereafter, the targeting abilities of EGFRmAb-SPIONs with MRI were qualitatively and quantitatively assessed in EGFR-positive C6 glioma cells in vitro and in a Wistar rat model bearing C6 glioma in vivo. Furthermore, the preliminary biocompatibility and toxicity of EGFRmAb-SPIONs were evaluated in normal rats through hematology assays and histopathologic analyses. Statistical analysis was performed using one-way analysis of variance and Student t-test, with a significance level of p < .05. From the results of EGFRmAb-SPION characterizations, the average particle size was 10.21 nm and the hydrodynamic diameter was 161.5 +/- 2.12 nm. The saturation magnetization was 55 emu/g.Fe, and T-2 relaxivity was 92.73 s(-1) mM(-1) in distilled water. The preferential accumulation of the EGFRmAb-SPIONs within glioma and subsequent MRI contrast enhancement were demonstrated both in vitro in C6 cells and in vivo in rats bearing C6 glioma. After intravenous administration of EGFRmAb-SPIONs, T-2-weighted MRI of the rat model with brain glioma exhibited an apparent hypointense region within glioma from 2 to 48 hours. The maximal image contrast was reached at 24 hours, where the signal intensity decreased and the R-2 value increased by 30% compared to baseline. However, T-2-weighted imaging of the rat model administered with SPIONs showed no visible signal changes within the tumor over the same time period. Moreover, no evident toxicities in vitro and in vivo with EGFRmAb-SPIONs were clearly identified based on the laboratory examinations. EGFRmAb-SPIONs could potentially be employed as a targeted contrast agent in the molecule-specific diagnosis of brain glioma in MRI.
基金：
National Natural Sciences Foundation of China [30870702, 81171308]; National Program of the Ministry of Science and Technology of China [2011BAI08B10]; National Basic Research Program of China (973 Program) [2012CB932500, 2015CB931800, 2015CB931802]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|3 区生物
小类|3 区生化研究方法3 区核医学
最新[2025]版：
大类|4 区医学
小类|4 区生化研究方法4 区核医学
JCR分区：
出版当年[2013]版：
Q2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3BIOCHEMICAL RESEARCH METHODS
最新[2024]版：
Q2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3BIOCHEMICAL RESEARCH METHODS
通讯机构：[*1]Tongji Hosp, Dept Radiol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714)：
Mu Ketao,Zhang Shun,Ai Tao,et al.Monoclonal Antibody-Conjugated Superparamagnetic Iron Oxide Nanoparticles for Imaging of Epidermal Growth Factor Receptor-Targeted Cells and Gliomas[J].MOLECULAR IMAGING.2015,14:doi:10.2310/7290.2015.00002.
APA：
Mu, Ketao,Zhang, Shun,Ai, Tao,Jiang, Jingjing,Yao, Yihao...&Zhu, Wenzhen.(2015).Monoclonal Antibody-Conjugated Superparamagnetic Iron Oxide Nanoparticles for Imaging of Epidermal Growth Factor Receptor-Targeted Cells and Gliomas.MOLECULAR IMAGING,14,
MLA：
Mu, Ketao,et al."Monoclonal Antibody-Conjugated Superparamagnetic Iron Oxide Nanoparticles for Imaging of Epidermal Growth Factor Receptor-Targeted Cells and Gliomas".MOLECULAR IMAGING 14.(2015)
